Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) [Original Articles]

Conclusions:
MGIB occurred more frequently with HD-ER than warfarin. The rates of life-threatening or fatal GIB were low and similar with both HD-ER and warfarin. Clinical outcomes were generally favorable. The correlation between dose, trough edoxaban level, and the risk of GIB risk suggests GIB is exposure-related.

Clinical Trial Registration:
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00781391.

Source: Circulation: Cardiovascular Quality and Outcomes - May 10, 2018 Category: Cardiology Authors: Aisenberg, J., Chatterjee-Murphy, P., Friedman Flack, K., Weitz, J. I., Ruff, C. T., Nordio, F., Mercuri, M. F., Choi, Y., Antman, E. M., Braunwald, E., Giugliano, R. P. Tags: Atrial Fibrillation, Risk Factors, Complications, Mortality/Survival Original Articles Source Type: research